InsiderSignal.AI

InsiderSignal.ai

RVMD - Revolution Medicines, Inc.

Insider Sale by Anders Jack (CFO)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

6 days ago, Anders Jack, serving as CFO at Revolution Medicines, Inc. (RVMD), sold 2,753 shares at $99.48 per share, for a total transaction value of $273,870.00. Following this transaction, Anders Jack now holds 125,512 shares of RVMD.

This sale represents a 2.00% decrease in Anders Jack's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Tuesday, March 17, 2026 and publicly disclosed via SEC Form 4 filing on Thursday, March 19, 2026, 2 days after the trade was made.

Revolution Medicines, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Anders Jack

CFO

Jack Anders is the Chief Financial Officer (CFO) of Revolution Medicines, Inc. (RVMD), a clinical-stage biopharmaceutical company focused on developing small molecule therapies for RAS-dependent cancers.[[1]](https://fintool.com/app/research/companies/RVMD/people/jack-anders)[[2]](https://www.marketbeat.com/instant-alerts/revolution-medicines-nasdaqrvmd-cfo-jack-anders-sells-10000-shares-2026-01-09/)[[6]](https://www.revmed.com/team/jack-anders/) Aged 48, he has served in this role since September 2022, after joining the company in August 2018 as Vice President of Finance and advancing to Senior Vice President of Finance in March 2021, where he built and led the finance function during pre-IPO scale-up.[[1]](https://fintool.com/app/research/companies/RVMD/people/jack-anders)[[6]](https://www.revmed.com/team/jack-anders/) Anders holds a B.A. in Economics with an emphasis in Accounting from UCLA and is a former certified public accountant with early career experience in PwC’s life sciences practice.[[1]](https://fintool.com/app/research/companies/RVMD/people/jack-anders) His prior roles include Vice President of Finance at Depomed, Inc. (2006–2018), and finance/accounting managerial positions at Elan Pharmaceuticals, Yahoo!, Novellus Systems, providing him with expertise across biotech, tech, and industrial sectors.[[1]](https://fintool.com/app/research/companies/RVMD/people/jack-anders) In 2024, under his tenure, RVMD achieved key milestones including an $863 million public equity financing, 130% attainment of corporate goals, and his individual performance rated at 125%; he recently sold 10,000 shares on January 7, 2026, reducing his ownership to 108,065 shares.[[1]](https://fintool.com/app/research/companies/RVMD/people/jack-anders)[[2]](https://www.marketbeat.com/instant-alerts/revolution-medicines-nasdaqrvmd-cfo-jack-anders-sells-10000-shares-2026-01-09/)[[4]](https://www.tradingview.com/news/tradingview:436bb2d65668d:0-revolution-medicines-executives-sell-shares/)

View full insider profile →

Trade Price

$99.48

Quantity

2,753

Total Value

$273,870.00

Shares Owned

125,512

Trade Date

Tuesday, March 17, 2026

6 days ago

SEC Filing Date

Thursday, March 19, 2026

Filed 2 days after trade

HEALTHCAREBIOTECHNOLOGY

About Revolution Medicines, Inc.

Company Overview

No company information available
View news mentioning RVMD

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/4923356

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime